Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron*, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, Mark Dolev, Shay Menascu, David Magalashvili, Shlomo Flechter, Uri Givon, Diana Guber, Polina Sonis, Rina Zilkha-Falb, Michael Gurevich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

Original languageEnglish
Article number577746
JournalJournal of Neuroimmunology
Volume361
DOIs
StatePublished - 15 Dec 2021
Externally publishedYes

Funding

FundersFunder number
Blindness and Visual Disorders
Clair and Amedee Maratier Institute
Laura Schwarz-Kipp Research Fund for Autoimmune Diseases
Sackler Faculty of Medicine
Sheba MS Center
Merck
Tel Aviv University

    Keywords

    • COVID-19
    • Disease modifying treatments
    • Humoral immunity
    • IgG antibody
    • Multiple sclerosis
    • Vaccination

    Fingerprint

    Dive into the research topics of 'Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study'. Together they form a unique fingerprint.

    Cite this